GO
Loading...

Enter multiple symbols separated by commas

Europe Top News and Analysis Ireland

More

  • Sept 3- Medtronic Plc reported a better-than-expected 70 percent rise in quarterly revenue, helped by higher sales of its heart and vascular devices in the United States and the Covidien acquisition. Dublin- based Medtronic's revenue rose to $7.27 billion from $4.27 billion a year earlier. Medtronic said sales in its cardiac and vascular business, which makes...

  • Medtronic profit jumps 47 pct Thursday, 3 Sep 2015 | 7:33 AM ET

    Sept 3- Medical device maker Medtronic Plc reported a 47 percent rise in quarterly adjusted net income, helped by higher sales across all its divisions. The Dublin- based company's adjusted profit rose to $1.46 billion, or $1.02 per share, in the first quarter ended July 31 from $992 million, or 99 cents per share, a year earlier. This is the second quarter to include...

  • Medtronic tops Street 1Q forecasts on sales boost Thursday, 3 Sep 2015 | 7:30 AM ET

    The average estimate of 16 analysts surveyed by Zacks Investment Research was for earnings of $1.01 per share. Fourteen analysts surveyed by Zacks expected $7.03 billion. Medtronic expects full-year adjusted earnings in the range of $4.30 to $4.40 per share.

  • Schengen: Europe's open borders in question Wednesday, 2 Sep 2015 | 6:35 AM ET

    Schengen, on the vine-flanked Moselle where old enemies France and Germany meet, gave its name 30 years ago to the code which removed border controls between most European states. "It's not Schengen that's the problem," the commissioner in charge of it, Dimitris Avramopoulos, told Reuters as Budapest, Vienna and Berlin bicker about what to do with thousands of...

  • PARIS— With more and more refugees appearing in Europe daily this summer, cities and towns are grappling with a basic but crucial problem: Where can they all sleep? Portable shipping containers are being converted into refugee apartments in Germany, which saw nearly half of Europe's overall 400,000 asylum applications in the first half of the year.

  • Medtronic to spend $458M on heart valve developer Tuesday, 25 Aug 2015 | 1:07 PM ET

    Medical device maker Medtronic will pay up to $458 million for a privately held company that is developing a heart valve replacement. The Dublin- based company said Tuesday that it will pay $408 million at the closing of its deal for Twelve Inc. and then make another $50 million milestone-based payment. U.S.-traded shares of Medtronic PLC climbed about 2.4...

  • LONDON, Aug 13- Baxalta wants Shire to improve on its $30 billion bid significantly before it will engage in talks, while its Dublin- based rival could sweeten its offer if it gets to see the U.S. biotech company's books, according to sources on both sides. Bolstered by the backing of its shareholders, Baxalta's management is digging in by scorning Shire's initial...

  • DUBLIN, Aug 13- A housing shortage and the possibility of Britain leaving the European Union are among the key economic and social risks to Ireland's economic recovery, a government report said on Thursday. On Britain's planned EU membership referendum, the report said a fundamental change to the role of the United Kingdom in the EU, or a period of continuing...

  • Shares of Mallinckrodt, which makes generic and specialty drugs as well as medical imaging agents, were little changed in afternoon trading on Monday. Dublin- based Mallinckrodt said it would focus on selling more of Therakos's devices in the United States, where it is approved only for a form of blood cancer. Mallinckrodt's purchase of Therakos from...

  • *Baxalta CEO says can get to Shire bid value on its own. LONDON, Aug 10- Shire Chief Executive Flemming Ornskov is stepping up his campaign to get Baxalta to the negotiating table as he pushes the benefits a $30 billion takeover offer to the U.S. biotech company's shareholders. Shares in Shire and Baxalta both rose on Monday, helped by a bullish note from Cowen analyst...

  • Shares of Mallinckrodt, which makes generic and specialty drugs as well as medical imaging agents, were little changed in afternoon trading on Monday. Dublin- based Mallinckrodt said it would focus on selling more of Therakos's devices in the United States, where it is approved only for a form of skin cancer. Mallinckrodt's purchase of Therakos from investment...

  • Shire CEO steps up drive to get Baxalta board talking Monday, 10 Aug 2015 | 11:20 AM ET

    LONDON, Aug 10- Shire Chief Executive Flemming Ornskov is stepping up his campaign to get Baxalta to the negotiating table as he pushes the benefits a $30 billion takeover offer to the U.S. biotech company's shareholders. He has a fight on his hands, with investors in newly listed Baxalta arguing he must pay more, although one person close to the Dublin- based...

  • *Mallinckrodt shares up flat in early trading. Aug 10- Dublin- based drugmaker Mallinckrodt Plc said it would buy immunotherapy company Therakos Inc in a deal valued at about $1.33 billion, its second major acquisition this year aimed at strengthening its hospital offerings. Mallinckrodt's purchase of Therakos from investment firm The Gores Group comes...

  • UPDATE 2-Allergan reports better-than-expected revenue Thursday, 6 Aug 2015 | 9:33 AM ET

    Aug 6- Irish drugmaker Allergan Plc reported better-than-expected revenue for the first full quarter since the merger of Actavis and Allergan. Allergan, which changed its name from Actavis after the deal closed, said adding signature drugs like Botox and eye drops Restasis boosted branded products sales five-fold to $3.71 billion in the second quarter...

  • Aug 6- Botox-maker Allergan Plc posted a better-than-expected quarterly adjusted profit as sales of branded drugs rose, helped by acquisition of new products. Allergan did not provide an update to its sales forecast for the full year. Dublin, Ireland- based Allergan's net revenue for the quarter more than doubled to $5.76 billion.

  • July 28- Ingersoll-Rand Plc, the maker of Trane airconditioners and Thermo King refrigeration units, forecast a lower-than-expected current-quarter profit, citing slow growth in its industrial business. The Dublin, Ireland- based company said it expects third-quarter adjusted earnings of $1.15 to $1.19 per share. The company's net profit attributable to...

  • TEL AVIV, July 27- Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms. It also will allow Dublin- based Allergan, the third-largest generic drugmaker in the United States, to focus on branded drugs...

  • TEL AVIV, July 26- After months of sparring in a hostile takeover bid for rival Mylan NV, Teva Pharmaceutical's move to buy Allergan Plc's generic drug business instead could be a smoother ride that will bring bigger returns, faster. Israel- based Teva, the world's largest generic drugmaker, is in advanced talks to buy Allergan's generic drugs unit for between $40-...

  • July 25- Teva Pharmaceutical Industries Ltd is in advanced talks to buy Allergan Plc's generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV, according to a person familiar with the matter. Jerusalem- based Teva, which has offered to buy Mylan for $40 billion, is now close to an agreement to acquire Dublin- based Allergan's...

  • ATHENS, July 16- European creditors moved cautiously towards re-opening funding to Greece's stricken economy on Thursday, hours after a fractious Greek parliament approved a tough bailout program aimed at preventing a chaotic exit from the euro. Prime Minister Alexis Tsipras won the backing of parliament in the early hours of Thursday for the stringent...